Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Proprietary DehydraTECH™ Platform: Lexaria owns and operates the patented DehydraTECH™ drug delivery technology, providing a unique and protected solution for enhancing the performance of various active ingredients.
Extensive Global Patent Portfolio: The company maintains a growing and robust portfolio of issued and pending patents worldwide, offering significant intellectual property protection for its core technology across diverse applications.
Broad Application Versatility: DehydraTECH™ can be applied to a wide array of substances including cannabinoids, nicotine, anti-viral compounds, anti-inflammatory drugs, and other APIs, opening numerous market opportunities.
Risks
Regulatory Approval Uncertainty: Failure to secure or delays in obtaining necessary regulatory approvals (e.g., FDA) for DehydraTECH-enhanced products could prevent market entry and revenue generation.
Intellectual Property Protection Challenges: The core value of Lexaria lies in its DehydraTECH™ patent portfolio; any challenges, expirations, or inability to enforce these patents could severely diminish its competitive advantage.
Clinical Trial Failure Risk: Development of new applications for DehydraTECH™ involves high-risk clinical trials, and failure to demonstrate efficacy or safety could halt product development and lead to significant losses.
Tuesday
Jun 23, 9:29 AM
Over a week ago
Jun 17, 9:35 AM
Jun 9, 9:31 AM
Apr 29, 9:13 AM
Apr 23, 9:12 AM
Apr 21, 9:24 AM
Apr 15, 9:16 AM
Apr 1, 9:21 AM
Mar 26, 9:22 AM
Mar 4, 9:26 AM
Feb 5, 9:22 AM
Jan 22, 9:23 AM
Jan 12, 9:49 AM
Dec 30, 9:24 AM
Dec 29, 5:24 PM
Dec 26, 6:04 AM
Dec 23, 9:34 AM
Dec 15, 8:17 AM
Nov 12, 9:13 AM
Oct 14, 4:03 PM
Oct 9, 9:23 AM
Sep 26, 3:33 PM